Please use this identifier to cite or link to this item:
Title: Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
Authors: Zhou, Jianbiao 
Chng, Wee-Joo 
Keywords: Bortezomib
Clonal evolution
Combination therapy
Drug resistance
Multiple myeloma
Proteasome inhibitor
Proteasome β5-subunit
Issue Date: 24-Sep-2019
Publisher: Baishideng Publishing Group Inc.
Citation: Zhou, Jianbiao, Chng, Wee-Joo (2019-09-24). Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.. World J Clin Oncol 10 (9) : 303-306. ScholarBank@NUS Repository.
Abstract: Multiple myeloma (MM) is a cancer caused by uncontrolled proliferation of antibody-secreting plasma cells in bone marrow, which represents the second most common hematological malignancy. MM is a highly heterogeneous disease and can be classified into a spectrum of subgroups based on their molecular and cytogenetic abnormalities. In the past decade, novel therapies, especially, the first-in-class proteasome inhibitor bortezomib, have been revolutionary for the treatment of MM patients. Despite these remarkable achievements, myeloma remains incurable with a high frequency of patients suffering from a relapse, due to drug resistance. Mutation in the proteasome β5-subunit (PSMB5) was found in a bortezomib-resistant cell line generated via long-term coculture with increasing concentrations of bortezomib in 2008, but their actual implication in drug resistance in the clinic has not been reported until recently. A recent study discovered four resistance-inducing PSMB5 mutations from a relapsed MM patient receiving prolonged bortezomib treatment. Analysis of the dynamic clonal evolution revealed that two subclones existed at the onset of disease, while the other two subclones were induced. Protein structural modeling and functional assays demonstrated that all four mutations impaired the binding of bortezomib to the 20S proteasome, conferring different degrees of resistance. The authors further demonstrated two potential approaches to overcome drug resistance by using combination therapy for targeting proteolysis machinery independent of the 20S proteasome.
Source Title: World J Clin Oncol
ISSN: 22184333
DOI: 10.5306/wjco.v10.i9.303
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.pdfPublished version339.17 kBAdobe PDF



Page view(s)

checked on Sep 29, 2022


checked on Sep 29, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.